We're #hiring a new (Senior) Research Associate, In vivo pharmacology in San Carlos, California. Apply today or share this post with your network.
关于我们
Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.
- 网站
-
https://www.ardatx.com
Arda Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Francisco Bay Area，CA
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
获取路线
US，CA，San Francisco Bay Area
Arda Therapeutics员工
动态
-
Arda’s founders, CEO Adam Freund and CTO Remi-Martin Laberge, joined the Translating Aging podcast with host Chris Patil to explore their cutting-edge approach to treating chronic diseases. Adam and Remi discussed Arda’s origin and shared how Arda's single-cell-based discovery platform pinpoints pathogenic cells in conditions like fibrosis, allowing for targeted cell depletion instead of traditional pathway modification. They described the challenges and opportunities inherent to applying the immune-oncology toolbox to non-oncology diseases, and outlined their vision for antibody-based therapeutics that could offer long-lasting effects with intermittent dosing, improving patient quality of life and paving the way for future applications in aging.
This week we talk with the founders of Arda Therapeutics, a biotechnology company developing novel therapies to selectively eliminate harmful cell populations driving chronic diseases. In this episode, CEO Adam Freund and CTO Remi-Martin Laberge discuss their innovative approach to treating illnesses by identifying and removing specific pathogenic cell types — rather than trying to modify cellular behavior through traditional drug-based approaches. Translating Aging is produced by BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Episode: https://lnkd.in/gMhQ9sTf (click ‘FOLLOW’ for links to your favorite podcast platform) Podcast: https://lnkd.in/gvF4X-ka
-
-
Thanks to our new investors at Two Sigma Ventures for this excellent write-up. We are excited to work with you!
?? Announcing our latest investment: Arda Therapeutics! Arda is developing a novel approach to chronic disease treatment, starting with fibrosis. Their cell-depleting technology aims to eliminate specific disease-driving cells, rather than just modifying cell behavior. By combining advanced data science with cellular biology, Arda is working to address chronic diseases at their source. Link to Dusan Perovic & Elianna (Elizabeth) Knight's blog post on why we invested in Arda in the comments!
-
-
Arda is pleased to announce the closing of our $43M Series A financing to accelerate the development of precision cell-depleting biologics to treat chronic diseases. The new capital will be used to drive our existing I&I pipeline toward the clinic, expand into new indications, and scale our single cell discovery platform. Thank you to our investors Andreessen Horowitz, Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV (Google Ventures), Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels, and Exitfund. Learn more about our mission to deplete pathogenic cells to treat disease at www.ardatx.com!
-
We're #hiring a new Research Associate, In vivo pharmacology in San Carlos, California. Apply today or share this post with your network.
-
We're #hiring a new Research Associate/Senior Research Associate, Cell Biology in San Carlos, California. Apply today or share this post with your network.
-
We're #hiring a new Research Associate/Senior Research Associate, Protein Science in San Carlos, California. Apply today or share this post with your network.
-
Arda is proud to participate in the upcoming Annual IPF Summit. Arda Founder and CEO Adam Freund will highlight our exciting progress depleting pathogenic cells to treat pulmonary fibrosis.
With only 11 weeks to go and already over 100 experts confirmed to attend, this year’s audience warrants one of our most dynamic and engaged gatherings yet! Despite turbulence with unexpected failures rocking the industry, the overwhelming response from the community shows the dedication of drug developers to advance treatment options for IPF patients in need. This week only you can ???????? ???? ???? $?????? on your registration to the ?????? ?????? ???????????? ????????, and that doesn’t include the discounts for bringing a colleague! ??????????, ???????? ???????????????? ?????????????? ????????????, ???????? ??! View the program here:?https://ter.li/r7shqs Register here:?https://ter.li/cpcvjd ? What’s in store? ?? Two dedicated tracks (???????????????? ?????????????? & ?????????? ?????????????????????? and ???????? ?????????????????????? & ????????????????) featuring unmissable content, from leveraging the latest advancements in Pulmonary Fibrosis recapitulation to enhance preclinical modelling to evolving measures of progress: surrogate, exploratory and composite endpoints for earlier detection of clinical benefit ?? Return of the highly anticipated ?????????????????????? ?????????????? ???????????? ?????????????????? allowing you to interrogate recent failures by dissecting targets, MOA, chosen biomarkers, endpoints, patient populations and beyond to learn and take lessons learned into current therapeutic development ?? ?????????????? ???????? ?????? ???????????????? and developments at our exclusive poster session, gain visibility, demonstrate your thought leadership, and receive important feedback all whilst attracting the attention of industry stakeholders ?? Plus ????+ expert speakers, ??+ hours of face-to-face networking, ?? interactive discussion-based workshops + ???????? As the largest gathering of IPF professionals, this is a must-attend event for all IPF enthusiasts looking to propel innovative and efficacious pulmonary fibrosis therapeutics through phase 2 and beyond. ?? ??????’?? ???????????? – ???????? ???????????? ???????? ?? ???? ???????? ???????? ???????????? ???? ???????? ???? ???? $?????? ???? ???????? ????????????????????????! Register here:?https://ter.li/cpcvjd Adam Freund, Aditya Patel, Ahmed Mousa, Amy Case, Professor Bertil E. Lindmark, Bhavika Kaul,, Brian Windsor, Carmel Nanthakumar, Claire Emson, Kotton, Darrell, David Lagares, David Rowlands, Elaine Kilgour, Farida Ahangari, ???????????????? ????????????????, Gregory Cosgrove, Henrik Landgren, Imran Alibhai, Imre Noth, Ines Macias-Perez,, Jason McCarthy,, Jeffrey Bornstein, Jim Wu, Joe GN "Skip" Garcia,, Katie McCauley, Kjetil Ask, Lee Borthwick, Lida Hariri, ???????????????? ??????????????????, marilyn glassberg, Matthew Thomas, Peter George, Peter Smith, Piet Wigerinck, Steven Greenberg, ???????????? ??????????????, Thomas Fabre, Tim Oldham, Toby Maher, Vipin Kumar, Zbigniew Zaslona
-
-
We're thrilled to welcome Scott Turner as the new Chief Scientific Officer at Arda. Scott brings with him a wealth of experience and expertise, particularly in the development and translation of anti-fibrotic therapies. Prior to joining us, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and the development of their anti-fibrotic pipeline. His innovative approaches, including applying single-cell precision cut tissue slice data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. With Scott at the helm as our new CSO, we're confident that his expertise will be instrumental in advancing our lead programs towards the clinic and driving innovative approaches to achieve pathogenic cell depletion. Join us in extending a warm welcome to Scott as he embarks on this new journey with Arda! #Leadership #Innovation #CSO #Biotech #Fibrosis
-
-
We are thrilled to announce the much-deserved promotion of Arda co-founder Remi-Martin Laberge to Chief Technology Officer. Remi has been an invaluable asset to our team since the beginning, consistently demonstrating exceptional leadership,?scientific acumen, and a relentless drive for innovation. Remi's vision and dedication will?continue to?be instrumental in accelerating our development of medicines that deplete the pathogenic cell populations that drive chronic diseases. We are excited for the future of Arda under his leadership as CTO, and we look forward to achieving even greater success together! #Leadership #Innovation #Promotion #CTO #Biotech